CG Oncology, Inc.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—as well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Arthur Kuan

Employees

142

Headquarters

Dallas, TX, United States

Website

cgoncology.com